These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 33276038

  • 1. Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.
    Davis BH, Sangha R, Dillon C, Brown TM, Narayan R, Beasley M, McElderry T, Nolin TD, Limdi NA.
    Am J Kidney Dis; 2021 Jul; 78(1):151-153. PubMed ID: 33276038
    [No Abstract] [Full Text] [Related]

  • 2. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.
    Skripka A, Sychev D, Bochkov P, Shevchenko R, Krupenin P, Kogay V, Listratov A, Krainyaya A, Gurinovich O, Sokolova A, Napalkov D, Fomin V.
    High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):151-156. PubMed ID: 32215878
    [Abstract] [Full Text] [Related]

  • 3. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
    Antoniou T, Macdonald EM, Yao Z, Hollands S, Gomes T, Tadrous M, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network.
    CMAJ; 2017 Jan 09; 189(1):E4-E10. PubMed ID: 28246253
    [Abstract] [Full Text] [Related]

  • 4. Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.
    Stecher A, Vene N, Mavri A, Mijovski MB, Krevel B, Gradišek P.
    Eur J Anaesthesiol; 2017 Jun 09; 34(6):400-402. PubMed ID: 28459790
    [No Abstract] [Full Text] [Related]

  • 5. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
    Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M.
    J Thromb Haemost; 2015 Oct 09; 13(10):1790-8. PubMed ID: 26270886
    [Abstract] [Full Text] [Related]

  • 6. Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study.
    Harel Z, Mamdani M, Juurlink DN, Garg AX, Wald R, Yao Z, Gomes T.
    Can J Cardiol; 2016 Aug 09; 32(8):986.e17-22. PubMed ID: 26992571
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
    Kumar R, Smith RE, Henry BL.
    J Intensive Care Med; 2015 Dec 09; 30(8):462-72. PubMed ID: 24668159
    [Abstract] [Full Text] [Related]

  • 10. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
    Quintard H, Viard D, Drici MD, Ruetsch C, Samama CM, Ichai C.
    Thromb Haemost; 2017 Jan 05; 117(1):196-197. PubMed ID: 27734073
    [No Abstract] [Full Text] [Related]

  • 11. Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran.
    Ji Q, Xu Q, Wang Z, Li X, Lv Q.
    Eur J Clin Pharmacol; 2019 Mar 05; 75(3):321-328. PubMed ID: 30377709
    [Abstract] [Full Text] [Related]

  • 12. Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings.
    Darwiche W, Bejan-Angoulvant T, Dievart F, Babuty D, Angoulvant D, Fauchier L.
    Int J Cardiol; 2016 Mar 01; 206():89-92. PubMed ID: 26785030
    [No Abstract] [Full Text] [Related]

  • 13. Assessment of Predicted Rate and Associated Factors of Dabigatran-induced Bleeding Events in Malaysian Patients with Non-Valvular Atrial Fibrillation.
    Beshir SA, Yap LB, Sim S, Chee KH, Lo YL.
    J Pharm Pharm Sci; 2017 Mar 01; 20(1):365-377. PubMed ID: 29145930
    [Abstract] [Full Text] [Related]

  • 14. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW, van Ryn J, Reilly P, Hylek EM, Elsaesser A, Glund S, Pollack CV, Weitz JI.
    J Am Coll Cardiol; 2019 Oct 08; 74(14):1760-1768. PubMed ID: 31582135
    [Abstract] [Full Text] [Related]

  • 15. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
    Tsai LK, Lin HJ, Chua SK, Liao PC, Yang YP, Chou PC, Lee CW, Lin MJ, Chen HM, Yeh JT, Li YH.
    J Stroke Cerebrovasc Dis; 2018 Feb 08; 27(2):e27-e33. PubMed ID: 29122465
    [Abstract] [Full Text] [Related]

  • 16. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Goldhaber SZ, Schulman S, Eriksson H, Feuring M, Fraessdorf M, Kreuzer J, Schüler E, Schellong S, Kakkar A.
    Thromb Haemost; 2017 Nov 08; 117(11):2045-2052. PubMed ID: 29202209
    [Abstract] [Full Text] [Related]

  • 17. Screening coagulation tests are underutilised in patients on dabigatran presenting with thromboembolic or haemorrhagic events.
    Chin PK, Fox A, Marais M, Tiong J.
    Intern Med J; 2016 Feb 08; 46(2):240-1. PubMed ID: 26899894
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
    Martin JL, Esmaeili H, Manuel RC, Petrini M, Wiebe S, Maas H.
    J Cardiovasc Pharmacol Ther; 2018 Sep 08; 23(5):399-406. PubMed ID: 29695165
    [Abstract] [Full Text] [Related]

  • 20. Hemorrhagic pleuropericardial effusion secondary to dabigatran.
    Sanlés González I, de Tapia Majado B, Berrazueta Fernández JR.
    Med Clin (Barc); 2018 Jul 23; 151(2):e7-e8. PubMed ID: 29292107
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.